The disclosure relates to a method of producing induced beta cells from urine-derived cells, the method comprising providing urine-derived cells; inducing the urine-derived cells by culturing said urine-derived cells in a primary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a first period of time to obtain induced endoderm cells; inducing the induced endoderm cells by culturing said induced endoderm cells in a secondary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a second period of time to obtain induced pancreatic precursor cells; and inducing the induced pancreatic precursor cells by culturing said pancreatic precursor cells in a tertiary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a third period of time to obtain induced beta cells.

Disclosed are a cell population of human urine-derived cells positive for CD90, a cell population of myotubes induced from the cell population of the human urine-derived cells positive for CD90, and a method for producing a myotube derived from the human urine-derived cell, comprising a step of separating the human urine-derived cells positive for CD90.

The present disclosure relates to a cell obtaining method for creating NFT based on a cell image. The cell obtaining method includes the steps of separating a cell from a biological sample, obtaining a stem cell by treating the cell with a dedifferentiation inducer, differentiating the stem cell, acquiring an image of the differentiated cell; and converting the image of the differentiated cell into an NFT image, and creates the NFT using a vital image in a simple and easy way through non-invasive and non-medical procedures.

Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells.

A method for producing pancreatic endocrine cells, the method including introducing one or more genes of a GLIS family or one or more gene products thereof and a Neurogenin3 gene or one or more gene products thereof into somatic cells.

Provided herein are methods of treating a subject in need of treatment for a urological condition including administering urine stem cells to said subject in a treatment effective amount; and, in conjunction therewith, administering growth factors to said subject in an amount effective to promote differentiation of said stem cells into skeletal muscle cells. Compositions useful for the same are also provided.

A method is described for generating a novel cancer stem cell line that possesses characteristics associated with stem cells, by co-culturing a human immortalized cell line and bone marrow-derived mesenchymal stem cells, and the novel cancer stem cell line established thereby. This method is able to readily generate cancer stem cells that are low in the level of structural chromosomal aberrations and are excellent in oncogenicity, and is effectively applicable to the development of anti-cancer drugs and personalized drugs.

The present invention provides a method for inducing differentiation of motor neurons with less burden on a donor. The method for producing motor neurons from urine-derived cells according to the present invention includes a step of introducing into the urine-derived cell a transcription factor for inducing differentiation into a motor neuron. The transcription factor is introduced into the urine-derived cells by an adenoviral vector. The method of the present invention can further include a step of culturing the urine-derived cell into which the transcription factor has been introduced to obtain a cell positive for (I) at least one selected from the group consisting of Tuj1 and ISL1, and positive for (II) at least one selected from the group consisting of HB9, ChAT, and SMI32, preferably a cell positive for at least SMI 32 for (II).

A method for inducing reprogramming of neural stem cells from urine cells by introducing mRNAs of reprogramming factors Oct4, Sox2, Klf4, and Glis1 is disclosed. A composition for the prevention or treatment of neurological damage diseases with the neural stem cells induced by the method as an active ingredient is disclosed.